More than 23 million people in the U.S. suffer from rare and prevalent inflammatory diseases, including Still’s disease, idiopathic pulmonary disease – a type of lung disease that results in scarring of the lungs – and the rare skin condition bullous pemphigoid. But one Durham startup company is working to improve the lives of those patients with inflammatory diseases.
IMMvention Therapeutix is discovering and developing novel disease-modifying therapies that inhibit the inflammation caused by activation of the inflammasomes in inflammatory diseases. Led by CEO Anil Goyal, Ph.D., the company is making significant strides in treatments. The company’s name aptly comes from a combination of the words “immune” and “intervention.”
“We are working to improve the quality of life for those affected patients by removing the inflammation that causes inflammatory diseases, creating new treatments for both rare and prevalent diseases such as osteoarthritis and rheumatoid arthritis,” says Goyal. “Looking ahead, we are also targeting diseases that affect the brain, like Alzheimer’s disease and Parkinson’s disease.”